Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
← catalyst calendarSponsored by Genprex, Inc. (industry) · GNPX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
62estimated
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-09 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer Extensive Stage
Interventions
- Biological: quaratusugene ozeplasmid — also filed as REQORSA
- Biological: atezolizumab — also filed as TECENTRIQ
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1
measured First 21-days at each dose level
Progression-Free Survival Rate (PFSR) - Phase 2
measured 18-weeks from Day 1 of maintenance therapy
Permalink · GNPX's whole pipeline · Catalyst calendar · Every registered study · What changed